In less than two years, the Falsified Medicines Directive (FMD) will come into full effect in the UK. With the need to develop and implement a strategy to comply with the new directive, Rupert Taylor also discusses the profound impact on how pharma brands will need to approach compliance and the additional layers on the manufacturing chain.
The transformation of the pharmaceutical supply chain
Essentra Plc | 06/13/2017